Hemolytic-uremic syndrome epidemiology and demographics
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics |
|
FDA on Hemolytic-uremic syndrome epidemiology and demographics |
|
CDC on Hemolytic-uremic syndrome epidemiology and demographics |
|
Hemolytic-uremic syndrome epidemiology and demographics in the news |
|
Blogs on Hemolytic-uremic syndrome epidemiology and demographics |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
The highest proportion of HUS cases (15.3%) occurred among children aged <5 years. HUS affects female more than male and white race more than other races. Mortality is more commonly seen in elderly patients in which disease is less common but more dangerous[1].
Epidemiology and Demographics
Incidence
- In children less than 5 years of age, the incidence of HUS is approximately 8.5 per 100,000.[2]
Mortality rate
- In 2017, the mortality of hemolytic uremic syndrome (HUS) is estimated to approximately 10% .[3]
Age
- Patients of all age groups may develop hemolytic uremic syndrome (HUS).
- The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.[4]
- HUS commonly affects individuals younger than 5 years of age.[4]
Race
- HUS usually affects individuals of the White race (82%).[5]
Gender
- HUS affects female more than male. Approximately 59% of affected individuals are female.[5]
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
References
- ↑ Gould LH, Demma L, Jones TF, Hurd S, Vugia DJ, Smith K; et al. (2009). "Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006". Clin Infect Dis. 49 (10): 1480–5. doi:10.1086/644621. PMID 19827953.
- ↑ Mele, Caterina; Remuzzi, Giuseppe; Noris, Marina (2014). "Hemolytic uremic syndrome". Seminars in Immunopathology. 36 (4): 399–420. doi:10.1007/s00281-014-0416-x. ISSN 1863-2297.
- ↑ Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 Karpman, Diana; Loos, Sebastian; Tati, Ramesh; Arvidsson, Ida (2017). "Haemolytic uraemic syndrome". Journal of Internal Medicine. 281 (2): 123–148. doi:10.1111/joim.12546. ISSN 0954-6820.
- ↑ 5.0 5.1 Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga, Bernhard Lammle & James N. George (2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". American journal of hematology. 85 (11): 844–847. doi:10.1002/ajh.21833. PMID 20799358. Unknown parameter
|month=ignored (help)